Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 25, Issue 12, 2009, Pages 1249-1259

  Castro, Pedro ^a   Plana, Montserrat ^b   González, Raquel ^b   López, Anna ^b   Vilella, Anna ^b   Argelich, Roger ^b   Gallart, Teresa ^b   Pumarola, Tomàs ^b   Bayas, José M ^b   Gatell, José M ^b   García, Felipe ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; DIDANOSINE; DIPHTHERIA TETANUS VACCINE; EFAVIRENZ; HEPATITIS A VACCINE; INFLUENZA VACCINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MEASLES MUMPS RUBELLA VACCINE; NELFINAVIR; NEVIRAPINE; PLACEBO; PNEUMOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; STAVUDINE; TENOFOVIR; VARICELLA ZOSTER VACCINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS LOAD;

EID: 73149113364     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0015     Document Type: Article

References (52)

1. Brichacek B, Swindells S, Janoff EN, et al.: Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996;174:1191-1199.
2. Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-1230.
3. Virelizier JL: Cellular activation and human immunodeficiency virus infection. Curr Opin Immunol 1989;2:409-413.
4. Poli G and Fauci AS: The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992;8:191-197.
5. Lewis P, Hensel M, and Emerman M: Human immunodeficiency virus infection of cells arrested in the cell cycle.EMBO J 1992;11:3053-3058.
6. Kolber MA, Gabr AH, De La Rosa A, et al.: Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS 2002;16:537-542.
7. Binley JM, Schiller DS, Ortiz GM, et al.: The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis 2000;181:1249-1263.
8. Haslett PA, Nixon DF, Shen Z, et al.: Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis 2000; 181:1264-1272.
9. Kimura T, Yoshimura K, Nishihara K, et al.: Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J Infect Dis 2002;185:53-60.
10. Libois A, Lopez A, Garcia F, et al.: Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses 2006;22:657-666.
11. Garcia F, Plana M, Ortiz GM, et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-F40.
12. Plana M, Garcia F, Gallart T, et al.: Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998; 352:1194-1195.
13. Plana M, Garcia F, Oxenius A, et al.: Relevance of HIV-1- specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr 2004;36:791-799.
14. Garcia F, Lejeune M, Climent N, et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005;191:1680-1685.
15. CDC. Simultaneous administration of varicella vaccine and other recommended childhood vaccines-United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001;50:1058-1061.
16. Mast EE, Weinbaum CM, Fiore AE, et al.: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. MMWR Recomm Rep 2006; 55:1-33.
17. Gunthard HF, Wong JK, Spina CA, et al.: Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000;181: 522-531.
18. Havlir DV, Bassett R, Levitan D, et al.: Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001;286:171-179.
19. Raboud JM, Rae S, Woods R, et al.: Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 2002;16:1627-1632.
20. Greub G, Cozzi-Lepri A, Ledergerber B, et al.: Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002;16:1967-1969.
21. Moore AL, Youle M, Lipman M, et al.: Raised viral load in patients with viral suppression on highly active antiretroviral therapy: Transient increase or treatment failure? AIDS 2002;16:615-618.
22. Easterbrook PJ, Ives N, Waters A, et al.: The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/ml. AIDS 2002 16 1521-1527
23. Miller LG, Golin CE, Liu H, et al.: No evidence of an association between transient HIV viremia ("blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis 2004;189:1487-1496.
24. Sungkanuparph S, Overton ET, Seyfried W, et al.: Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse- transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005;41:1326-1332.
25. De Rosa SC, Lu FX, Yu J, et al.: Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173:5372-5380.
26. Couch RB: Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis 1999;28: 548-551.
27. Staprans SI, Hamilton BL, Follansbee SE, et al.: Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-1737.
28. Ramilo O, Hicks PJ, Borvak J, et al.: T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996; 15:197-203.
29. McCune JM: The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001;410:974-979.
30. Hazenberg MD, Hamann D, Schuitemaker H, et al.: T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock. Nat Immunol 2000;1:285-289.
31. Grossman Z, Meier-Schellersheim M, Sousa AE, et al.: CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause? Nat Med 2002;8:319-323.
32. Silvestri G and Feinberg MB: Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest 2003; 112:821-824.
33. Di Genova G, Roddick J, McNicholl F, et al.: Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. Blood 2006;107:2806-2813.
34. Schmitz JE, Kuroda MJ, Santra S, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
35. Papasavvas E, Grant RM, Sun J, et al.: Lack of persistent drugresistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS 2003;17:2337-2343.
36. Florence E, Garcia F, Plana M, et al.: Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption. Clin Infect Dis 2004;39: 569-574.
37. Papasavvas E, Kostman JR, Thiel B, et al.: HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol 2006;26: 40-54.
38. Jansen CA, van Baarle D, and Miedema F: HIV-specific CD4+ T cells and viremia: Who's in control? Trends Immunol 2006;27:119-124.
39. Jansen CA, De Cuyper IM, Hooibrink B, et al.: Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study. Blood 2006;107:1427-1433.
40. Chehimi J, Campbell DE, Azzoni L, et al.: Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002;168:4796-4801.
41. Azzoni L, Papasavvas E, Chehimi J, et al.: Sustained impairment of IFN-gamma secretion in suppressed HIVinfected patients despite mature NK cell recovery: Evidence for a defective reconstitution of innate immunity. J Immunol 2002;168:5764-5770.
42. Pantaleo G, Soudeyns H, Demarest JF, et al.: Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997;94:9848-9853.
43. Appay V, Nixon DF, Donahoe SM, et al.: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000;192:63-75.
44. Thiebaut R, Pellegrin I, Chene G, et al.: Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 40010(6) cells/l. AIDS 2005;19:53-61.
45. Fernandez Guerrero ML, Rivas P, Molina M, et al.: Long-term follow-up of asymptomaticHIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis 2005;41:390-394.
46. El Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ countguided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
47. Glesby MJ, Hoover DR, Farzadegan H, et al.: The effect of influenza vaccinationonhumanimmunodeficiency virus type 1 load: A randomized, double-blind, placebo-controlled study. J Infect Dis 1996;174:1332-1336.
48. Tasker SA, O'Brien WA, Treanor JJ, et al.: Effects of influenza vaccination in HIV-infected adults: A double-blind, placebocontrolled trial. Vaccine 1998;16:1039-1042.
49. Tasker SA, Treanor JJ, Paxton WB, et al.: Efficacy of influenza vaccination in HIV-infected persons. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1999;131: 430-433.
50. Goetz MB, Feikin DR, Lennox JL, et al.: Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients. AIDS 2002;16: 1421-1423.
51. Kemper CA, Haubrich R, Frank I, et al.: Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: A double-blind, randomized, placebo-controlled trial. J Infect Dis 2003;187:1327-1331.
52. Wallace MR, Brandt CJ, Earhart KC, et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIVinfected subjects. Clin Infect Dis 2004;39:1207-1213.